Skip to Content

Tritec (ranitidine bismuth citrate) Disease Interactions

There are 3 disease interactions with Tritec (ranitidine bismuth citrate):


H2 Antagonists (Includes Tritec) ↔ Gi Bleeding

Severe Potential Hazard, Moderate plausibility

Applies to: Gastrointestinal Hemorrhage

Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools. These might be serious conditions and the diagnosis needs to be ruled out.


Ranitidine Bismuth Citrate (Includes Tritec) ↔ Porphyria

Severe Potential Hazard, Moderate plausibility

Applies to: Porphyria

Ranitidine may rarely precipitate acute porphyria attacks. Therapy with ranitidine bismuth citrate should be avoided in patients with a history of acute porphyria.


  1. "Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome, Research Triangle Park, NC.

Ranitidine Bismuth Citrate (Includes Tritec) ↔ Renal Dysfunction

Moderate Potential Hazard, High plausibility

Applies to: Renal Dysfunction

Ranitidine bismuth citrate is primarily eliminated by the kidney. Therapy with ranitidine bismuth citrate should be administered cautiously in patients with renal impairment, and avoided in patients with creatinine clearance < 25 mL/min.


  1. Lacey LF, Frazer NM, Keene ON, Smith JT "Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR122311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB)." Eur J Clin Pharmacol 47 (1994): 177-80
  2. "Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome, Research Triangle Park, NC.

Tritec (ranitidine bismuth citrate) drug Interactions

There are 264 drug interactions with Tritec (ranitidine bismuth citrate)

Tritec (ranitidine bismuth citrate) alcohol/food Interactions

There is 1 alcohol/food interaction with Tritec (ranitidine bismuth citrate)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.